INTRODUCTION: Persons carrying mutations for hereditary cancer syndromes are at high risk for the development of tumors at an early age, as well as the synchronous or metachronous development of multiple tumors of the corresponding tumor spectrum. The genetic causes of many hereditary cancer syndromes have already been identified. About 5% of all cancers are part of a hereditary cancer syndrome. METHODS: Selective literature review, including evidence-based guidelines and recommendations. RESULTS: Clinical criteria are currently available according to which many hereditary cancer syndromes can be diagnosed or suspected and which point the way to further molecular genetic analysis. A physician can easily determine whether these criteria are met by directed questioning about the patient's personal and family medical history. The identification of the causative germ line mutation in the family allows confirmation of the diagnosis in the affected individual and opens up the option of predictive testing in healthy relatives. DISCUSSION: Mutation carriers for hereditary cancer syndromes need long-term medical surveillance in a specialized center. It is important that these persons should be identified in the primary care setting and then referred for genetic counseling if molecular genetic testing is to be performed in a targeted, rational manner.
INTRODUCTION:Persons carrying mutations for hereditary cancer syndromes are at high risk for the development of tumors at an early age, as well as the synchronous or metachronous development of multiple tumors of the corresponding tumor spectrum. The genetic causes of many hereditary cancer syndromes have already been identified. About 5% of all cancers are part of a hereditary cancer syndrome. METHODS: Selective literature review, including evidence-based guidelines and recommendations. RESULTS: Clinical criteria are currently available according to which many hereditary cancer syndromes can be diagnosed or suspected and which point the way to further molecular genetic analysis. A physician can easily determine whether these criteria are met by directed questioning about the patient's personal and family medical history. The identification of the causative germ line mutation in the family allows confirmation of the diagnosis in the affected individual and opens up the option of predictive testing in healthy relatives. DISCUSSION: Mutation carriers for hereditary cancer syndromes need long-term medical surveillance in a specialized center. It is important that these persons should be identified in the primary care setting and then referred for genetic counseling if molecular genetic testing is to be performed in a targeted, rational manner.
Authors: W Schmiegel; C Pox; G Adler; W Fleig; U R Fölsch; P Frühmorgen; U Graeven; W Hohenberger; A Holstege; T Junginger; T Kühlbacher; R Porschen; P Propping; J F Riemann; R Sauer; T Sauerbruch; H J Schmoll; M Zeitz; H K Selbmann Journal: Z Gastroenterol Date: 2004-10 Impact factor: 2.000
Authors: C Lamberti; E Mangold; C Pagenstecher; M Jungck; D Schwering; M Bollmann; J Vogel; D Kindermann; R Nikorowitsch; N Friedrichs; B Schneider; F Houshdaran; I G H Schmidt-Wolf; W Friedl; P Propping; T Sauerbruch; R Büttner; M Mathiak Journal: Digestion Date: 2006-03-03 Impact factor: 3.216
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Tom Walsh; Silvia Casadei; Kathryn Hale Coats; Elizabeth Swisher; Sunday M Stray; Jake Higgins; Kevin C Roach; Jessica Mandell; Ming K Lee; Sona Ciernikova; Lenka Foretova; Pavel Soucek; Mary-Claire King Journal: JAMA Date: 2006-03-22 Impact factor: 56.272
Authors: S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: H F A Vasen; G Möslein; A Alonso; S Aretz; I Bernstein; L Bertario; I Blanco; S Bülow; J Burn; G Capella; C Colas; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; H Järvinen; J-P Mecklin; P Møller; T Myrhøi; F M Nagengast; Y Parc; R Phillips; S K Clark; M Ponz de Leon; L Renkonen-Sinisalo; J R Sampson; A Stormorken; S Tejpar; H J W Thomas; J Wijnen Journal: Gut Date: 2008-01-14 Impact factor: 23.059
Authors: Verena Steinke; Christoph Engel; Reinhard Büttner; Hans Konrad Schackert; Wolff H Schmiegel; Peter Propping Journal: Dtsch Arztebl Int Date: 2013-01-18 Impact factor: 5.594
Authors: Michelle L Matthews; Bradley S Hurst; Paul B Marshburn; Rebecca S Usadi; Margaret A Papadakis; Terry Sarantou Journal: Obstet Gynecol Int Date: 2012-03-18